-
公开(公告)号:US20110294758A1
公开(公告)日:2011-12-01
申请号:US13115647
申请日:2011-05-25
申请人: Feng Tian , Qun Dang , G. Sridhar Prasad , Wenyu Li , Brett C. Bookser , Nicholas Brian Raffaele , Mark D. Erion
发明人: Feng Tian , Qun Dang , G. Sridhar Prasad , Wenyu Li , Brett C. Bookser , Nicholas Brian Raffaele , Mark D. Erion
IPC分类号: A61K31/675 , C07F9/38 , C07F9/44 , C07F9/36 , A61P3/00 , A61P3/10 , A61P3/08 , A61P5/50 , A61P1/16 , C07F9/30 , C07F9/6574
CPC分类号: C07F9/65586 , A61K31/44 , C07C233/11 , C07D213/81 , C07F9/3834 , C07F9/4021 , C07F9/58 , C07F9/65031 , C07F9/650952 , C07F9/6512 , C07F9/653 , C07F9/6539 , C07F9/65392 , C07F9/65395 , C07F9/65397 , C07F9/6541 , C07F9/655345 , C07F9/65583 , C07F9/6561 , C07F9/65616 , C07F9/657181
摘要: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
摘要翻译: 本发明提供具有葡糖多糖激活剂活性的新颖的式I和II化合物及其药学上可接受的盐和共结晶。 本发明进一步提供包含其的药物组合物以及治疗,预防,延迟发病时间或降低其中指示出一种或多种葡萄糖激酶激活剂的疾病或病症的发展或进展的风险的方法,包括 1型和2型糖尿病,糖耐量异常,胰岛素抵抗和高血糖。 本发明还提供了制备式I和II化合物的方法,包括其盐和共结晶,以及包含其的药物组合物。
-
公开(公告)号:US08940927B2
公开(公告)日:2015-01-27
申请号:US13115647
申请日:2011-05-25
申请人: Feng Tian , Qun Dang , G. Sridhar Prasad , Wenyu Li , Brett C. Bookser , Nicholas Brian Raffaele , Mark D. Erion
发明人: Feng Tian , Qun Dang , G. Sridhar Prasad , Wenyu Li , Brett C. Bookser , Nicholas Brian Raffaele , Mark D. Erion
IPC分类号: C07F9/28 , C07C233/11 , A61K33/42 , A61K31/166 , A61P3/10 , A61P3/08 , A61P3/04 , C07F9/6558 , C07F9/38 , C07F9/40 , C07F9/58 , C07F9/6503 , C07F9/6509 , C07F9/6512 , C07F9/653 , C07F9/6539 , C07F9/6553 , C07F9/6561 , C07F9/6571
CPC分类号: C07F9/65586 , A61K31/44 , C07C233/11 , C07D213/81 , C07F9/3834 , C07F9/4021 , C07F9/58 , C07F9/65031 , C07F9/650952 , C07F9/6512 , C07F9/653 , C07F9/6539 , C07F9/65392 , C07F9/65395 , C07F9/65397 , C07F9/6541 , C07F9/655345 , C07F9/65583 , C07F9/6561 , C07F9/65616 , C07F9/657181
摘要: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
摘要翻译: 本发明提供具有葡糖激酶活化剂活性的式I和II的新化合物及其药学上可接受的盐和共结晶。 本发明进一步提供包含其的药物组合物以及治疗,预防,延迟发病时间或降低其中指示出一种或多种葡萄糖激酶激活剂的疾病或病症的发展或进展的风险的方法,包括 1型和2型糖尿病,糖耐量异常,胰岛素抵抗和高血糖。 本发明还提供了制备式I和II化合物的方法,包括其盐和共结晶,以及包含其的药物组合物。
-
3.
公开(公告)号:US09248089B2
公开(公告)日:2016-02-02
申请号:US14356387
申请日:2012-11-07
申请人: Feng Tian , Daniel Liang Zou , Lingyun Ji
发明人: Feng Tian , Daniel Liang Zou , Lingyun Ji
摘要: The present disclosure is directed to peptide-based compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure may inhibit neurotransmitter release and muscle contraction as a treatment for wrinkles. The compounds of the disclosure may be used for pathological neuronal exocytosis-mediated cosmetic and/or therapeutic purposes.
摘要翻译: 本公开涉及基于肽的化合物,其衍生物,药学上可接受的盐,溶剂合物和水合物。 本公开的化合物和组合物可以抑制作为皱纹治疗的神经递质释放和肌肉收缩。 本公开的化合物可用于病理性神经元胞吐作用介导的化妆品和/或治疗目的。
-
公开(公告)号:US20150285790A1
公开(公告)日:2015-10-08
申请号:US14679024
申请日:2015-04-05
申请人: Feng Tian , Daniel Liang Zou , Lingyun Ji
发明人: Feng Tian , Daniel Liang Zou , Lingyun Ji
CPC分类号: G01N33/5304 , B01L1/00 , B01L3/508 , B01L3/52 , B01L2300/02 , B01L2300/0672 , B01L2300/0841 , G01N1/38 , G01N33/5302 , G01N2035/00524
摘要: The present disclosure provides an automated bioprocessing device, which may comprises a processing machine, one or more removable washing cartridges. The removable washing cartridge may comprise a shell, a sample holder, a washing basin, a waste container, a reagent container, a rotation mechanism, and a poking mechanism. The processing machine may comprise a motor, which may provide power to the inserted removable washing cartridge.
摘要翻译: 本公开提供了一种自动生物处理装置,其可以包括处理机器,一个或多个可移除的洗涤筒。 可移除的清洗盒可以包括壳体,样本保持器,洗涤盆,废物容器,试剂容器,旋转机构和戳戳机构。 加工机器可以包括电机,其可以向插入的可移除的清洗盒提供电力。
-
公开(公告)号:US09086921B2
公开(公告)日:2015-07-21
申请号:US13460547
申请日:2012-04-30
CPC分类号: G06F9/5016 , G06F9/45533 , G06F17/30 , G06F17/30306
摘要: Memory of a database management system (DBMS) that is running in a virtual or physical machine is managed using techniques that that reduce the effect of memory swaps on the performance of the physical or virtual machine. One such technique includes the steps of determining a swap rate while the database application is in an executing state, and decreasing the size of memory space available to the database application if the swap rate is above a threshold.
摘要翻译: 在虚拟或物理机器中运行的数据库管理系统(DBMS)的内存使用可以减少内存互换对物理机或虚拟机性能的影响的技术进行管理。 一种这样的技术包括在数据库应用处于执行状态时确定交换速率的步骤,以及如果交换速率高于阈值则减小数据库应用可用的存储空间的大小。
-
公开(公告)号:US09074010B2
公开(公告)日:2015-07-07
申请号:US13208136
申请日:2011-08-11
申请人: Joseph Sheffer , Thea Norman , Richard D. Dimarchi , Anna-Maria A. Hays Putnam , Feng Tian , Stephanie Chu , Denise Krawitz , Ho Sung Cho
发明人: Joseph Sheffer , Thea Norman , Richard D. Dimarchi , Anna-Maria A. Hays Putnam , Feng Tian , Stephanie Chu , Denise Krawitz , Ho Sung Cho
CPC分类号: C07K14/47 , A61K38/00 , C07K14/765 , C07K19/00 , C07K2319/00
摘要: Modified human plasma polypeptides or Fc and uses thereof are provided.
摘要翻译: 提供了修饰的人血浆多肽或Fc及其用途。
-
7.
公开(公告)号:US09020545B2
公开(公告)日:2015-04-28
申请号:US13201405
申请日:2010-08-17
申请人: Feng Tian
发明人: Feng Tian
CPC分类号: H04L1/0009 , H04B17/318 , H04L1/0003 , H04L2001/0092 , H04W52/262
摘要: The present invention discloses a link adaptation method, a base station and a terminal in a LTE system, wherein the method comprises: a terminal respectively calculating differences between a measured reference signal received power (RSRP) of a home service cell and the RSRPs of multiple adjacent cells; the terminal reporting the maximum difference in the differences to a base station; and the base station determining a modulation and coding scheme (MCS) for the terminal according to the maximum difference. The present invention does not introduce new overhead of the system, simplifies the flow of the AMC, and therefore improves the frequency spectrum efficiency of the system.
摘要翻译: 本发明公开了一种LTE系统中的链路适配方法,基站和终端,其中,所述方法包括:分别计算家庭业务小区的测量参考信号接收功率(RSRP)与多个RSRP之间的差异的终端 相邻细胞; 终端报告与基站的差异的最大差异; 并且基站根据最大差异确定终端的调制和编码方案(MCS)。 本发明不引入系统的新开销,简化了AMC的流程,从而提高了系统的频谱效率。
-
8.
公开(公告)号:US08586340B2
公开(公告)日:2013-11-19
申请号:US11580223
申请日:2006-10-11
申请人: Meng-Lin Tsao , Feng Tian , Peter Schultz
发明人: Meng-Lin Tsao , Feng Tian , Peter Schultz
CPC分类号: C12P21/02 , C07K14/005 , C07K2319/00 , C07K2319/50 , C12N7/00 , C12N9/93 , C12N15/1037 , C12N15/67 , C12N2795/14122
摘要: The invention relates to posttranslational modification of phage-displayed polypeptides. These displayed polypeptides comprise at least one unnatural amino acid, e.g., an aryl-azide amino acid such as p-azido-L-phenylalanine, or an alkynyl-amino acid such as para-propargyloxyphenylalanine, which are incorporated into the phage-displayed fusion polypeptide at a selected position by using an in vivo orthogonal translation system comprising a suitable orthogonal aminoacyl-tRNA synthetase and a suitable orthogonal tRNA species. These unnatural amino acids advantageously provide targets for posttranslational modifications such as azide-alkyne [3+2] cycloaddition reactions and Staudinger modifications.
摘要翻译: 本发明涉及噬菌体展示多肽的翻译后修饰。 这些显示的多肽包含至少一个非天然氨基酸,例如芳基叠氮氨基酸如对叠氮基-L-苯丙氨酸或炔基 - 氨基酸如对 - 炔丙氧基苯丙氨酸,其被并入噬菌体展示的融合物 通过使用包含合适的正交氨酰-tRNA合成酶和合适的正交tRNA物质的体内正交翻译系统,在选定位置上的多肽。 这些非天然氨基酸有利地提供翻译后修饰的靶标,例如叠氮炔 - 炔[3 + 2]环加成反应和施陶丁格修饰。
-
公开(公告)号:US08434882B2
公开(公告)日:2013-05-07
申请号:US12702321
申请日:2010-02-09
申请人: Feng Tian , Tay-Jian Liu , Yuan Long
发明人: Feng Tian , Tay-Jian Liu , Yuan Long
IPC分类号: F21V23/06
CPC分类号: F21S9/022 , F21K9/278 , F21V29/506 , F21V29/83 , F21Y2103/10 , F21Y2105/10 , F21Y2115/10 , Y10T307/625
摘要: An LED lamp includes an optical part, a heat dissipation member and an electric part. The optical part includes a hollow light penetrable tube and an LED module received in the tube. The heat dissipation member is received in the tube to mount the LED module thereon. The electric part include a circuit board and a rechargeable battery arranged in the tube, and two end covers arranged at two opposite ends of the tube. The LED module is provided with at least one first LED and at least one second LED. The at least one first LED and the at least one second LED cooperatively function as a main light source to provide normal illumination when an external AC power source is supplied normally. The at least one second LED independently function as an auxiliary light source to provide emergency illumination when the external AC power source is interrupted.
摘要翻译: LED灯包括光学部件,散热部件和电气部件。 光学部件包括容纳在管中的中空透光管和LED模块。 散热构件被容纳在管中以将LED模块安装在其上。 电气部件包括布置在管中的电路板和可再充电电池,并且布置在管的两个相对端的两个端盖。 LED模块设置有至少一个第一LED和至少一个第二LED。 当正常地提供外部AC电源时,所述至少一个第一LED和所述至少一个第二LED协同地用作主光源以提供正常照明。 至少一个第二LED独立地用作辅助光源,以在外部AC电源中断时提供紧急照明。
-
公开(公告)号:US20120262064A1
公开(公告)日:2012-10-18
申请号:US13368920
申请日:2012-02-08
CPC分类号: H03F3/20 , H01J37/32082 , H01J37/32183 , H03F1/565 , H03F3/195 , H03F2200/321 , H03F2200/387 , H03F2200/391 , H03F2200/393 , H03F2200/451 , H03H7/40 , Y10T307/305
摘要: A system and method are provided for delivering power to a dynamic load. The system includes a power supply providing DC power having a substantially constant power open loop response, a power amplifier for converting the DC power to RF power, a sensor for measuring voltage, current and phase angle between voltage and current vectors associated with the RF power, an electrically controllable impedance matching system to modify the impedance of the power amplifier to at least a substantially matched impedance of a dynamic load, and a controller for controlling the electrically controllable impedance matching system. The system further includes a sensor calibration measuring module for determining power delivered by the power amplifier, an electronic matching system calibration module for determining power delivered to a dynamic load, and a power dissipation module for calculating power dissipated in the electrically controllable impedance matching system.
摘要翻译: 提供了一种将功率传递给动态负载的系统和方法。 该系统包括提供具有基本上恒定的功率开环响应的DC电力的电源,用于将DC功率转换为RF功率的功率放大器,用于测量与RF功率相关联的电压和电流矢量之间的电压,电流和相位角的传感器 ,电可控阻抗匹配系统,用于将功率放大器的阻抗修改为动态负载的至少基本匹配的阻抗;以及用于控制电可控阻抗匹配系统的控制器。 该系统还包括用于确定由功率放大器输出的功率的传感器校准测量模块,用于确定输送到动态负载的功率的电子匹配系统校准模块,以及用于计算在电气可控阻抗匹配系统中消耗的功率的功率耗散模块。
-
-
-
-
-
-
-
-
-